New challenges in drug discovery

Bano, Iqra; Butt, Usman Dawood; Mohsan, Syed Agha Hassnain

doi:10.1016/b978-0-323-91376-8.00021-5

Cited by 6 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, an average of approximately 50 drugs per year have been approved by the USA Federal Drug Administration Center for Drug Evaluation and Research for therapeutic use, which is an increase compared to the historic average of 34 drugs approved per year since 1993[2]. Nevertheless, developing novel and safe drugs poses several challenges and requires significant time and resources to validate clinical efficacy, toxicity, sensitivity, and specificity[3,4]. To expedite the process for discovering new drugs, several experimental and computational approaches have been developed to enable high throughput small molecule screening campaigns[5,6].…”

Section: Introductionmentioning

confidence: 99%

Similarity of drug targets to human microbiome metaproteome promotes pharmacological promiscuity

Beaudoin,

Norget,

Hala

et al. 2024

Preprint

View full text Add to dashboard Cite

Similarity between candidate drug targets and human proteins is commonly assessed to minimize the occurrence of side effects. Although numerous drugs have been found to disrupt the health of the human microbiome, no comprehensive comparison between established drug targets and the human microbiome metaproteome has yet been conducted. Therefore, herein, sequence and structure alignments between human and pathogen drug targets and representative human gut, oral, and vaginal microbiome metaproteomes were performed. Both human and pathogen drug targets were found to be similar in sequence, function, structure, and drug binding capacity to proteins in diverse pathogenic and non-pathogenic bacteria from all three microbiomes. The gut metaproteome was identified as particularly susceptible overall to off-target effects. Certain symptoms, such as infections and immune disorders, may be more common among drugs that non-selectively target host microbiota. These findings suggest that similarities between human microbiome metaproteomes and drug target candidates should be routinely checked.

show abstract